A Prospective Sub-Study of the Global Hypophosphatasia Registry (NCT05234567)
A Prospective Observational Sub-Study of the Global Hypophosphatasia Registry to Describe the Potential Risk of Immune-Mediated Loss of Pharmacological Effect of Asfotase Alfa in Participants With Hypophosphatasia
🩺 Plain-English Summary (8th-Grade Level)
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Hartford, Connecticut
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Clinical Trial Site — Hartford, Connecticut
- Clinical Trial Site — Chicago, Illinois
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Kansas City, Missouri
- Clinical Trial Site — Mineola, New York
- Clinical Trial Site — Cincinnati, Ohio
- Clinical Trial Site — Columbus, Ohio
- Clinical Trial Site — Pittsburgh, Pennsylvania
- Clinical Trial Site — Nashville, Tennessee
- Clinical Trial Site — Salt Lake City, Utah
- Clinical Trial Site — Charlottesville, Virginia
- Clinical Trial Site — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (855) 752-2356
Email: clinicaltrials@alexion.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hypophosphatasia
- Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa — Indianapolis, Indiana
- Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP — Baltimore, Maryland
- Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa — Hartford, Connecticut
- Natural History Study of Patients With Hypophosphatasia (HPP) — Durham, North Carolina
Explore by condition: All Hypophosphatasia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.